X0508 4 2026-02-02 false 0001517022 Akebia Therapeutics, Inc. AKBA 0001591467 Butler John P. C/O AKEBIA THERAPEUTICS, INC. 245 FIRST STREET CAMBRIDGE MA 02142 true true false false CEO and President true Common Stock 2026-02-02 4 S false 46660.00 1.39 D 3417189.00 D Common Stock 2026-02-02 4 S false 96065.00 1.39 D 3321124.00 D Common Stock 2026-02-02 4 S false 114891.00 1.39 D 3206233.00 D Common Stock 2026-02-02 4 A false 175250.00 1.41 A 3381483.00 D Common Stock 2026-02-02 4 S false 83689.00 1.39 D 3297794.00 D Common Stock 159928.00 I Held by Dorothy Butler Revocable Trust November 20, 2007 This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2023. This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 8, 2025. This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2024. This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2025. As reported in February 2025, the Reporting Person was granted performance-based restricted stock units ("PSUs") pursuant to the Issuer's 2023 Stock Incentive Plan, as amended. Each PSU right represents a contingent right to receive one share of the Issuer's common stock. One-half of the total number of shares of common stock underlying the PSUs vests on the later of (i) the first anniversary of the grant date and (ii) the date that the Compensation Committee certifies that the average closing price of the Issuer's common stock equals or exceeds $3.50 over a 30-day trading period (the "Stock Price Hurdle 1 Performance Condition"), subject to the reporting persons continuous employment through the applicable vesting date. In July2025, the Compensation Committee certified that the Stock Price Hurdle 1 Performance Condition was met during the performance period and therefore one-half of the PSUs vested on January 31, 2026. This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-half of the reporting person's performance stock units granted on January 31, 2025. /s/ Carolyn M. Rucci, attorney-in-fact for John P. Butler 2026-02-04